Related Experiment Video

Updated: Jul 1, 2026

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Terbium-161 might be superior to lutetium-177 for oligometastases

Elif Hindié1, Alexandre Larouze2, Clément Morgat3

  • 1Department of Nuclear Medicine, CHU Bordeaux, Hôpital Haut-Lévêque, 33604 Pessac, France; Service de Médecine Nucléaire, CHU de Bordeaux, Université de Bordeaux, Talence, France; Institut Universitaire de France, Paris, France.

The Lancet. Oncology
|June 29, 2026
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry
10:54

Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry

Published on: February 4, 2017

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Experiment Videos

Last Updated: Jul 1, 2026

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
10:47

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging

Published on: February 3, 2015

Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry
10:54

Preparation and Evaluation of 99mTc-labeled Tridentate Chelates for Pre-targeting Using Bioorthogonal Chemistry

Published on: February 4, 2017

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction
09:44

Pretargeted Radioimmunotherapy Based on the Inverse Electron Demand Diels-Alder Reaction

Published on: January 29, 2019

Related Concept Videos

Nuclear Transmutation03:20

Nuclear Transmutation

Nuclear transmutation is the conversion of one nuclide into another. It can occur by the radioactive decay of a nucleus, or the reaction of a nucleus with another particle. The first manmade nucleus was produced in Ernest Rutherford’s laboratory in 1919 by a transmutation reaction, the bombardment of one type of nuclei with other nuclei or with neutrons. Rutherford bombarded nitrogen-14 atoms with high-speed α particles from a natural radioactive isotope of radium and observed protons being...

Articles linked to this work by shared authors, journal, and citation graph.

Sleep's influence on susceptibility to motion sickness in parabolic flights and virtual reality: An exploratory study.

Journal of vestibular research : equilibrium & orientation·2026

Prospective study on the [18F]FDOPA PET/CT role in the management of medullary thyroid cancer patients with high residual calcitonin level after surgery.

European journal of nuclear medicine and molecular imaging·2026

Fully GMP-complient radiosynthesis of [161Tb]Tb-PSMA-1 using the miniAiO synthesizer for clinical translation.

EJNMMI radiopharmacy and chemistry·2026

Prognostic impact of Dmax on baseline FDG-PET/CT in newly diagnosed multiple myeloma.

Haematologica·2026

[177Lu]Lu-dota-tate versus sunitinib in patients with metastatic progressive neuroendocrine tumours of the pancreas (OCLURANDOM): a randomised, controlled, phase 2 trial.

The Lancet. Oncology·2026

Persistent lymph node uptake on [18 F]-FDG PET-CT after neoadjuvant chemotherapy: a major predictive factor of disease-free survival in MIBC.

World journal of urology·2026

Development and external validation of a new prognostic model for metastatic clear cell renal cell carcinoma: a preregistered analysis using data from randomised clinical trials in the checkpoint inhibitor era.

The Lancet. Oncology·2026

Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial.

The Lancet. Oncology·2026

Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet. Oncology·2026

An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial.

The Lancet. Oncology·2026

Challenges in the use of the European Society for Radiotherapy and Oncology-European Organisation for Research and Treatment of Cancer oligometastatic disease classification system in ovarian cancer.

The Lancet. Oncology·2026

Tumour-infiltrating lymphocytes and breast radiotherapy: perspectives from the International Immuno-Oncology Biomarker Working Group.

The Lancet. Oncology·2026

In-silico investigation into optimal photoacoustic probe design using a digital thyroid phantom.

Journal of biomedical optics·2026

DenseUNet for Breast Cancer Segmentation in Histopathological Images.

Journal of medical signals and sensors·2026

Capturing fine-grained spatial details in brain tumor MRI via multi-module feature enhancement.

Frontiers in oncology·2026

En bloc resection and trapezius island flap reconstruction of giant extracranial Schobinger stage III/Yakes type IV arteriovenous malformations involving the orbital region.

JPRAS open·2026

Three-dimensional rotational angiography-based multimodal fusion imaging for preoperative neurovascular assessment in intracranial meningiomas: a retrospective technical feasibility study of 72 cases.

Frontiers in neurology·2026

In vivo targeted fluorescence imaging and magnetic resonance imaging of E. coli bacterial infection using polymyxin B-conjugated and polyacrylic acid-grafted GdEuO3 nanoparticles.

Chemical communications (Cambridge, England)·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us